Biotech bank balances were again in focus Monday morning, with Tango Therapeutics cutting preclinical work to stretch its ...

Lexeo Therapeutics laid off 15% of its staff last month as part of a wider plan to siphon $20 million from its wider pipeline ...

Dynavax’s battle with activist investor Deep Track Capital over the biopharma’s direction has heated up again as the ...

California biotech NGM Bio is slimming down as the company pivots focus, shedding around 75% of staff, pausing development of ...

The FDA has approved its first at-home collection kit that allows women to screen themselves for human papillomavirus (HPV) ...

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

The FDA has appointed its first chief artificial intelligence officer, with an eye on supporting the agency’s internal IT ...

RallyBio is steering around more tight corners as it announces a further 40% reduction in staffers just weeks after ...

Sanofi has scrapped its collaboration with IGM Biosciences, eliminating the biotech’s l | Sanofi has scrapped its ...

A phase 3 trial of Aldeyra Therapeutics’ dry eye disease prospect has hit its primary endpoint, preparing the biotech to seek ...

Qilu Pharmaceutical is paying 280 million Chinese yuan ($38 million) for a licensing and collaboration deal with fellow China ...

The National Institutes of Health (NIH) has laid off 250 more employees, with this round of cuts hitting 50 workers at the ...